Clinical trial NCT01321255 - References

Myocardial Infarction — Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

Citation(s)

•   Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A
  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.
•   Antithrombotic Trialists' Collaboration
  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. Erratum in: BMJ 2002 Jan 19;324(7330):141.
•   Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R
  Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007 Dec 15;370(9604):2044-53. Epub 2007 Dec 11. Review. Erratum in: Lancet. 2007 Dec 15;370(9604):2004.
•   Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators
  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.
•   Bangalore S, Kamalakkannan G, Parkar S, Messerli FH
  Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 Aug;120(8):713-9.
•   Beaglehole R, Ebrahim S, Reddy S, Voûte J, Leeder S; Chronic Disease Action Group
  Prevention of chronic diseases: a call to action. Lancet. 2007 Dec 22;370(9605):2152-7. Epub 2007 Dec 11. Review.
•   Beaglehole R, Reddy S, Leeder SR
  Poverty and human development: the global implications of cardiovascular disease. Circulation. 2007 Oct 23;116(17):1871-3. Review.
•   Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N; Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD)
  Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003 Jun 18;289(23):3106-16.
•   Bosworth HB
  Medication treatment adherence. Chapter 6, 147-94. In: Bosworth H, Oddone, E., Weinberger, M., ed. In:
•   Chiuve SE, McCullough ML, Sacks FM, Rimm EB
  Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation. 2006 Jul 11;114(2):160-7. Epub 2006 Jul 3.
•   Combination Pharmacotherapy and Public Health Research Working Group
  Combination pharmacotherapy for cardiovascular disease. Ann Intern Med. 2005 Oct 18;143(8):593-9. Review. Erratum in: Ann Intern Med. 2006 Jul 4;145(1):79.
•   Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S
  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006 Aug 12;368(9535):581-8. Review.
•   Danchin N, Cambou JP, Hanania G, Kadri Z, Genès N, Lablanche JM, Blanchard D, Vaur L, Clerson P, Guéret P; USIC 2000 investigators
  Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J. 2005 Dec;150(6):1147-53.
•   Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG
  Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med. 2006 Apr 10;166(7):787-96.
•   Davies AR, Smeeth L, Grundy EM
  Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. Eur Heart J. 2007 Sep;28(17):2142-7. Epub 2007 Jul 18.
•   Dickson M, Plauschinat CA
  Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8(1):45-50.
•   DiMatteo MR, Lepper HS, Croghan TW
  Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7.
•   DiMatteo MR
  Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004 Mar;23(2):207-18.
•   DiMatteo MR
  Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004 Mar;42(3):200-9.
•   Doval HCT, C
  D. Prevención secundaria de las enfermedades cardiovasculares. In: Evidencias en Cardiología. Buenos Aires: GEDIC; 2008.
•   EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events
  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001 Mar 31;357(9261):995-1001.
•   European Cardiovascular Disease Statistics
  British Heart Foundation and European Heart Network. 2005
•   European Health Heart Charter
  Available at www.heartcharter.eu
•   Ezzati M, Lopez AD
  Estimates of global mortality attributable to smoking in 2000. Lancet. 2003 Sep 13;362(9387):847-52.
•   Fletcher GF, Bufalino V, Costa F, Goldstein LB, Jones D, Smaha L, Smith SC Jr, Stone N
  Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol. 2007 Mar 27;99(6C):1E-35E. Epub 2007 Mar 5. Review.
•   Fuster V, Sanz G
  A polypill for secondary prevention: time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med. 2007 Apr;4(4):173.
•   Gaziano TA, Galea G, Reddy KS
  Scaling up interventions for chronic disease prevention: the evidence. Lancet. 2007 Dec 8;370(9603):1939-46. Review.
•   Gaziano TA
  Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart. 2008 Feb;94(2):140-4. doi: 10.1136/hrt.2007.128785. Review.
•   Gehi A, Haas D, Pipkin S, Whooley MA
  Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med. 2005 Nov 28;165(21):2508-13.
•   Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA; Global Registry of Acute Coronary Events Investigators
  Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003 Oct 27;163(19):2345-53.
•   Heras M, Marrugat J, Arós F, Bosch X, Enero J, Suárez MA, Pabón P, Ancillo P, Loma-Osorio A, Rodríguez JJ, Subirana I, Vila J; en representación de los investigadores del estudio PRIAMHO
  [Reduction in acute myocardial infarction mortality over a five-year period]. Rev Esp Cardiol. 2006 Mar;59(3):200-8. Spanish.
•   Herrick TM, Million RP
  Tapping the potential of fixed-dose combinations. Nat Rev Drug Discov. 2007 Jul;6(7):513-4.
•   Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS
  Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006 Sep 25;166(17):1842-7.
•   Jackevicius CA, Li P, Tu JV
  Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008 Feb 26;117(8):1028-36. doi: 10.1161/CIRCULATIONAHA.107.706820.
•   kaplan W
  LR. Priority medicines for Europe and the World; 2004 November.
•   Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group
  Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5.
•   Kotseva K
  Global preventive policies. Strategies at European and worldwide level. Rev Esp Cardiol. 2008 Sep;61(9):960-70. English, Spanish.
•   Kristensen SD, Baumgartner H, Drexler H, Eeckhout E, Filippatos G, Gitt AK, Linde C, Pierard LA, Poldermans D, Schunkert H, Sipido KR, van der Wall EE, Fox K, Bax JJ; European Society of Cardiology
  Highlights of the 2007 scientific sessions of the European Society of Cardiology Vienna, Austria, September 1-5, 2007. J Am Coll Cardiol. 2007 Dec 18;50(25):2421-30.
•   Kroenke K, Spitzer RL, Williams JB
  The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.
•   Law MR, Wald NJ, Rudnicka AR
  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 Jun 28;326(7404):1423. Review.
•   Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ
  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006 May 27;367(9524):1747-57.
•   Mackenbach JP, Stirbu I, Roskam AJ, Schaap MM, Menvielle G, Leinsalu M, Kunst AE; European Union Working Group on Socioeconomic Inequalities in Health
  Socioeconomic inequalities in health in 22 European countries. N Engl J Med. 2008 Jun 5;358(23):2468-81. doi: 10.1056/NEJMsa0707519. Erratum in: N Engl J Med. 2008 Sep 18;359(12):e14.
•   Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, Shengelia B
  WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ. 2005 Nov;83(11):820-9. Epub 2005 Nov 10.
•   Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M
  The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279-88.
•   Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA
  Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004 Feb 17;109(6):745-9.
•   Pan F, Chernew ME, Fendrick AM
  Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008 May;23(5):611-4. doi: 10.1007/s11606-008-0544-x. Epub 2008 Feb 21.
•   Pharma 2020: the vision
  Which path will you take? (Accessed at http://www.pwc.com/pharma.)
•   Radloff LS
  The CES-D scale: a self-report depression scale for research in the general population. Applied Psychology Measurements 1977;1.
•   Rasmussen JN, Chong A, Alter DA
  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 Jan 10;297(2):177-86.
•   Reddy KS
  Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public Health Nutr. 2002 Feb;5(1A):231-7. Review.
•   Reddy KS
  Is a multidrug regimen cost-effective for the prevention of cardiovascular disease in resource-poor countries? Nat Clin Pract Cardiovasc Med. 2007 Mar;4(3):130-2. Epub 2007 Jan 30.
•   Reddy KS
  The preventive polypill--much promise, insufficient evidence. N Engl J Med. 2007 Jan 18;356(3):212.
•   Sanz GA
  [Risk stratification in acute coronary syndromes: an unresolved issue]. Rev Esp Cardiol. 2007 Oct;60 Suppl 3:23-30. Spanish.
•   Sleight P, Pouleur H, Zannad F
  Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006 Jul;27(14):1651-6. Epub 2006 Apr 7. Review.
•   Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute
  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16;113(19):2363-72. Erratum in: Circulation. 2006 Jun 6;113(22):e847.
•   Trust WW
  Second World Health Organization & Wellcome Trust Workshop. In: Secondary Prevention of Cardiovascular Disease in Low & Middle Income Countries - Building the Evidence Base on Secondary Prevention of CVD. 2007 6-8 June; London; 2007
•   Wald NJ, Law MR
  A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28;326(7404):1419. Erratum in: BMJ. 2006 Sep;60(9):823. BMJ. 2003 Sep 13;327(7415):586.
•   Wise J
  Polypill holds promise for people with chronic disease. Bull World Health Organ. 2005 Dec;83(12):885-7. Epub 2006 Jan 30.
•   World Bank Report: Public Policy and the Challenge of Chronic Noncommunicable Diseases
  2007. (Accessed at http://siteresources.worldbank.org/INTPH/Resources/PublicPolicyandNCDsWorldBank2007FullReport.pdf.)
•   World Health Organization
  Price, availability and affordability. An international comparison of chronic disease medicines. Background report prepared for the WHO Plannig Meeting on the Global Initiative for Treatment of Chronic Diseases, Cairo, December 2005
•   Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators
  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52.

Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug

Details for clinical trial NCT01321255